I just finished up my review of Illumina.
I agree with @Savage87, it’s a field where it’s easy to get displaced without consistent investment into your own technology.
I was surprised at the high profit margin considering the reinvestment into the business, and their investment arm.
It’s super overpriced right now but it’s a really solid quality investment in my eyes, they have the kind of balance sheet you’d expect from a stable investment while still being in the healthcare space.
I have it down as a long term buy but right now the analyst estimates are largely out of date, meaning it might be worth holding off if you want to try and get it at a better price. We know Q2 is going to be rough and lower than expected, so an incoming discount might be due, or it’s already expected (given they announced lower than expected numbers.)